Search

Displaying results 1931 - 1940 of 8171 in total
  1. Drug

    Nitisinone

    go.drugbank.com/drugs/DB00348
    Approved

    Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1 and Alkaptonuria. It is sold under the brand names Orfadin and Harliku.

    Synonyms: 2-(alpha,alpha,alpha-Trifluoro-2-nitro-p-tuluoyl)-1,3-cyclohexanedioneCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  2. Drug

    Epcoritamab

    go.drugbank.com/drugs/DB16672
    ApprovedInvestigational

    [L46516,L46556] In September 2023, epcoritamab was also approved in the EU for the same indication. … Epcoritamab is an IgG1-bispecific antibody that simultaneously binds to CD3 on T-cells and CD20 on B-cells.

  3. Drug

    Fidaxomicin

    go.drugbank.com/drugs/DB08874
    ApprovedInvestigational

    [A190501] Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug.

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A Inhibitors
  4. Drug

    Amiloride

    go.drugbank.com/drugs/DB00594
    ApprovedInvestigational

    A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and c...

    Mixtures: PLENACOR D, Nu-amilzide 5/50 Mg Tab
  5. Drug

    Ulobetasol

    go.drugbank.com/drugs/DB00596
    Approved

    [A215597] Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses.

  6. Drug

    Methsuximide

    go.drugbank.com/drugs/DB05246
    Approved

    Mesuximide (or methsuximide) is an anticonvulsant medication. It is sold by Pfizer under the name Petinutin.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Inhibitors
  7. Drug

    Ethosuximide

    go.drugbank.com/drugs/DB00593
    ApprovedInvestigational

    An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    PF-05175157

    go.drugbank.com/drugs/DB12096
    Investigational

    PF-05175157 has been used in trials studying the basic science and treatment of Acne Vulgaris, Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes Mellitus Type 2, and Diabetes Mellitus, Type 2, among

  9. Drug

    Triplizumab

    go.drugbank.com/drugs/DB30669
    Investigational

    triplizumab is a biologic drug. triplizumab is under investigation in clinical trial NCT06486220 (PFLL Combined With PD-1 Antibody With or Without FMT for Oligometastatic NPC,a Phase III ,Open, Randomized

  10. Drug

    Pimavanserin

    go.drugbank.com/drugs/DB05316
    ApprovedInvestigational

    In fact, pimavanserin is the first antipsychotic drug without D<sub>2</sub> blocking activity. … Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates